 |
2 Diseases |  |
32 Trials |
|
32 Trials |  |
1662 News |  |
| «12...13141516171819202122232425» |
- Cytovene (ganciclovir) / Roche, cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] INTENSIFICATION OF CMV PROPHYLAXIS WITH THE USE OF GANCICLOVIR DURING THE CONDITIONING IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. COMPARISON WITH A STANDARD STRATEGY. 113 PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3964;
Whit the caveat that in the group those who received ganciclovir there were more patients on steroids, our study shows that in the field of Haplo-PTCy the intensification of CMV prophylaxis with the addition of full dose of ganciclovir for seven days during the conditioning to the standard strategy does not decrease neither the incidence of CMV reactivation nor the time of first viremia in seropositive patients. With the availability of new medication for CMV prevention in the market it is worth to explore the use of it in this high risk population.
- Cytovene (ganciclovir) / Roche, cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] INTENSIFICATION OF CMV PROPHYLAXIS WITH THE USE OF GANCICLOVIR DURING THE CONDITIONING IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. COMPARISON WITH A STANDARD STRATEGY. 113 PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3963;
Whit the caveat that in the group those who received ganciclovir there were more patients on steroids, our study shows that in the field of Haplo-PTCy the intensification of CMV prophylaxis with the addition of full dose of ganciclovir for seven days during the conditioning to the standard strategy does not decrease neither the incidence of CMV reactivation nor the time of first viremia in seropositive patients. With the availability of new medication for CMV prevention in the market it is worth to explore the use of it in this high risk population.
- Cytovene (ganciclovir) / Roche, cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] INTENSIFICATION OF CMV PROPHYLAXIS WITH THE USE OF GANCICLOVIR DURING THE CONDITIONING IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. COMPARISON WITH A STANDARD STRATEGY. 113 PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3962;
Whit the caveat that in the group those who received ganciclovir there were more patients on steroids, our study shows that in the field of Haplo-PTCy the intensification of CMV prophylaxis with the addition of full dose of ganciclovir for seven days during the conditioning to the standard strategy does not decrease neither the incidence of CMV reactivation nor the time of first viremia in seropositive patients. With the availability of new medication for CMV prevention in the market it is worth to explore the use of it in this high risk population.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] INCIDENCE AND IMPACT OF EPSTEIN-BARR VIRUS EVENTS IN THE EARLY PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3955;
Despite better approaches with weekly surveillance, monitoring and pre-emptive therapy for EBV, EBV-events are associated with reduced overall survival. The impact of letermovir prophylaxis preventing CMV-events is expected to improve clinical management for CMV, but its impact on EBV-events is unknown.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] INCIDENCE AND IMPACT OF EPSTEIN-BARR VIRUS EVENTS IN THE EARLY PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3954;
Despite better approaches with weekly surveillance, monitoring and pre-emptive therapy for EBV, EBV-events are associated with reduced overall survival. The impact of letermovir prophylaxis preventing CMV-events is expected to improve clinical management for CMV, but its impact on EBV-events is unknown.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] INCIDENCE AND IMPACT OF EPSTEIN-BARR VIRUS EVENTS IN THE EARLY PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3953;
Despite better approaches with weekly surveillance, monitoring and pre-emptive therapy for EBV, EBV-events are associated with reduced overall survival. The impact of letermovir prophylaxis preventing CMV-events is expected to improve clinical management for CMV, but its impact on EBV-events is unknown.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] LETERMOVIR PROPHYLAXIS REDUCES INPATIENT RESOURCE CONSUMPTION BY BEING EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REAL-WORLD EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3949;
Letermovir dramatically lowered the cumulative incidence of CMV reactivation to the same extent as observed in the pivotal trial. In terms of resource consumption, letermovir substantially reduced hospitalisation needs for foscarnet application enabling health care providers to allocate inpatient resources to other patients in need.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] LETERMOVIR PROPHYLAXIS REDUCES INPATIENT RESOURCE CONSUMPTION BY BEING EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REAL-WORLD EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3948;
Letermovir dramatically lowered the cumulative incidence of CMV reactivation to the same extent as observed in the pivotal trial. In terms of resource consumption, letermovir substantially reduced hospitalisation needs for foscarnet application enabling health care providers to allocate inpatient resources to other patients in need.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] LETERMOVIR PROPHYLAXIS REDUCES INPATIENT RESOURCE CONSUMPTION BY BEING EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REAL-WORLD EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3947;
Letermovir dramatically lowered the cumulative incidence of CMV reactivation to the same extent as observed in the pivotal trial. In terms of resource consumption, letermovir substantially reduced hospitalisation needs for foscarnet application enabling health care providers to allocate inpatient resources to other patients in need.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CLINICAL EFFICACY OF LETERMOVIR PROPHYLAXIS FOR CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3925;
In terms of resource consumption, letermovir substantially reduced hospitalisation needs for foscarnet application enabling health care providers to allocate inpatient resources to other patients in need. Consistent with the phase III trial, our study shows that LET for the prophylaxis of CMV infection is safe, and considerably effective in a real-world setting.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CLINICAL EFFICACY OF LETERMOVIR PROPHYLAXIS FOR CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3924;
Consistent with the phase III trial, our study shows that LET for the prophylaxis of CMV infection is safe, and considerably effective in a real-world setting. Consistent with the phase III trial, our study shows that LET for the prophylaxis of CMV infection is safe, and considerably effective in a real-world setting.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CLINICAL EFFICACY OF LETERMOVIR PROPHYLAXIS FOR CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3923;
Consistent with the phase III trial, our study shows that LET for the prophylaxis of CMV infection is safe, and considerably effective in a real-world setting. Consistent with the phase III trial, our study shows that LET for the prophylaxis of CMV infection is safe, and considerably effective in a real-world setting.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] PREDICTION OF CMV REACTIVATION BY THE RECIPIENT IGG TITER BEFORE ALLO-HCT (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3913;
Recipient CMV-IgG titer should be considered in the risk stratification of CMV reactivation. Clinical Trial Registry: No clinical trial registry
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] PREDICTION OF CMV REACTIVATION BY THE RECIPIENT IGG TITER BEFORE ALLO-HCT (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3912;
Recipient CMV-IgG titer should be considered in the risk stratification of CMV reactivation. Clinical Trial Registry: No clinical trial registry
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] PREDICTION OF CMV REACTIVATION BY THE RECIPIENT IGG TITER BEFORE ALLO-HCT (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3911;
Recipient CMV-IgG titer should be considered in the risk stratification of CMV reactivation. Clinical Trial Registry: No clinical trial registry
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] EFFICACY OF LETERMOVIR FOR PROPHYLAXIS OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTI CENTER RETROSPECTIVE ANALYSIS AMONG JAPANESE PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3886;
Clinical Trial Registry: No clinical trial registry LTV effectively prevents or delays CMV reactivation, that possibly contributes to improve transplant outcome, although long-term follow up will be required.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] EFFICACY OF LETERMOVIR FOR PROPHYLAXIS OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTI CENTER RETROSPECTIVE ANALYSIS AMONG JAPANESE PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3885;
LTV effectively prevents or delays CMV reactivation, that possibly contributes to improve transplant outcome, although long-term follow up will be required. LTV effectively prevents or delays CMV reactivation, that possibly contributes to improve transplant outcome, although long-term follow up will be required.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] EFFICACY OF LETERMOVIR FOR PROPHYLAXIS OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTI CENTER RETROSPECTIVE ANALYSIS AMONG JAPANESE PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3884;
LTV effectively prevents or delays CMV reactivation, that possibly contributes to improve transplant outcome, although long-term follow up will be required. LTV effectively prevents or delays CMV reactivation, that possibly contributes to improve transplant outcome, although long-term follow up will be required.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] BASELINE CHARACTERISTICS AND EARLY POLY-FUNCTIONAL ASSESSMENT OF T CELLS TO IDENTIFY PATIENTS AT HIGHER RISK TO DEVELOP SEVERE HCMV REACTIVATION AFTER ALLOGENEIC HSCT (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3868;
Conversely to what reported by other authors, we also found a direct correlation between the amount of total and HCMV-specific CD4+/CD8+ T-cells detected one month after HSCT and the risk of HCMV reactivation requiring pre-emptive therapy. Taken together, these data suggest that poly-functional assessment of CD8+ T-cells may be used as an additional useful tool to better identify patients who will significantly benefit from anti-HCMV prophylaxis early after allo-HSCT.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] BASELINE CHARACTERISTICS AND EARLY POLY-FUNCTIONAL ASSESSMENT OF T CELLS TO IDENTIFY PATIENTS AT HIGHER RISK TO DEVELOP SEVERE HCMV REACTIVATION AFTER ALLOGENEIC HSCT (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3867;
Conversely to what reported by other authors, we also found a direct correlation between the amount of total and HCMV-specific CD4+/CD8+ T-cells detected one month after HSCT and the risk of HCMV reactivation requiring pre-emptive therapy. Taken together, these data suggest that poly-functional assessment of CD8+ T-cells may be used as an additional useful tool to better identify patients who will significantly benefit from anti-HCMV prophylaxis early after allo-HSCT.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] BASELINE CHARACTERISTICS AND EARLY POLY-FUNCTIONAL ASSESSMENT OF T CELLS TO IDENTIFY PATIENTS AT HIGHER RISK TO DEVELOP SEVERE HCMV REACTIVATION AFTER ALLOGENEIC HSCT (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3866;
Conversely to what reported by other authors, we also found a direct correlation between the amount of total and HCMV-specific CD4+/CD8+ T-cells detected one month after HSCT and the risk of HCMV reactivation requiring pre-emptive therapy. Taken together, these data suggest that poly-functional assessment of CD8+ T-cells may be used as an additional useful tool to better identify patients who will significantly benefit from anti-HCMV prophylaxis early after allo-HSCT.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] IMPACT OF CMV SEROSTATUS AND CMV REACTIVATION AFTER HAPLOIDENTICAL-SCT WITH PT-CY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3826;
CMV reactivation is associated with increased risk of developing grade 2-4 acute GVHD. We conclude that also in the platform of haplo-SCT with PT-Cy, letermovir prophylaxis may be given mainly to CMV seropositive recipients, that may benefit the most in terms of CMV reactivation, acute GVHD incidence and NRM.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] IMPACT OF CMV SEROSTATUS AND CMV REACTIVATION AFTER HAPLOIDENTICAL-SCT WITH PT-CY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3825;
CMV reactivation is associated with increased risk of developing grade 2-4 acute GVHD. We conclude that also in the platform of haplo-SCT with PT-Cy, letermovir prophylaxis may be given mainly to CMV seropositive recipients, that may benefit the most in terms of CMV reactivation, acute GVHD incidence and NRM.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] IMPACT OF CMV SEROSTATUS AND CMV REACTIVATION AFTER HAPLOIDENTICAL-SCT WITH PT-CY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3824;
CMV reactivation is associated with increased risk of developing grade 2-4 acute GVHD. We conclude that also in the platform of haplo-SCT with PT-Cy, letermovir prophylaxis may be given mainly to CMV seropositive recipients, that may benefit the most in terms of CMV reactivation, acute GVHD incidence and NRM.
- Prevymis (letermovir) / Merck (MSD), cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] PRIMARY LETERMOVIR PROPHYLAXIS IN CMV SEROPOSITIVE PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL LIFE EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3817;
The conditioning regimen was myeloablative (MAC) in 172 patients, thiotepa fludarabine busulfan (TBF, n=155) or total body irradiation 1200 rads (TBI, n=17) and reduced intensity/toxicities regimen (RIT) in 15 patients... Our experience demonstrates the efficacy of Letermovir in a real-world setting for the prevention of clinically significant CMV infection during the first 14 weeks after allogeneic HSCT in CMV-seropositive patients, without severe adverse events.
- Prevymis (letermovir) / Merck (MSD), cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] PRIMARY LETERMOVIR PROPHYLAXIS IN CMV SEROPOSITIVE PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL LIFE EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3816;
The conditioning regimen was myeloablative (MAC) in 172 patients, thiotepa fludarabine busulfan (TBF, n=155) or total body irradiation 1200 rads (TBI, n=17) and reduced intensity/toxicities regimen (RIT) in 15 patients... Our experience demonstrates the efficacy of Letermovir in a real-world setting for the prevention of clinically significant CMV infection during the first 14 weeks after allogeneic HSCT in CMV-seropositive patients, without severe adverse events.
- Prevymis (letermovir) / Merck (MSD), cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] PRIMARY LETERMOVIR PROPHYLAXIS IN CMV SEROPOSITIVE PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL LIFE EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3815;
The conditioning regimen was myeloablative (MAC) in 172 patients, thiotepa fludarabine busulfan (TBF, n=155) or total body irradiation 1200 rads (TBI, n=17) and reduced intensity/toxicities regimen (RIT) in 15 patients... Our experience demonstrates the efficacy of Letermovir in a real-world setting for the prevention of clinically significant CMV infection during the first 14 weeks after allogeneic HSCT in CMV-seropositive patients, without severe adverse events.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease. (Pubmed Central) - Jul 2, 2020
We describe here the use of letermovir in a 2-year-old immunocompromised child with ganciclovir-resistant cytomegalovirus disease who required extracorporeal membrane oxygenation. Detailed information on therapeutic-drug-monitoring measures and dosage adjustments for letermovir is provided.
- || Prevymis (letermovir) / Merck (MSD)
I think the point here is , don’t start letermovir prophy while detecable as most lit suggest to start when low or undetectable or if unreliable absorption . @DrNeilStone @OncIDPharmd @FranciscoMarty_ @PaulSaxMD @RazonableMD (Twitter) - Jun 25, 2020
- | Journal: New vaccines and antiviral drugs for cytomegalovirus. (Pubmed Central) - Jun 19, 2020
If there is evidence of control of CMV, this can be related to immune responses induced by the vaccine to define a correlate of protection. This review will summarise the published evidence available.
- |||| Prevymis (letermovir) / Merck (MSD)
Combination therapy: Happy to share my voodoo. 1) RIS guided by the absolute lymphocyte count (ALC). Sometimes despite aggressive reduction remains super low. 2) CMV IgG. 3) Combination therapy. We have used up to 960 daily of letermovir. 4) If the above fails we have considered CTL. (Twitter) - Jun 19, 2020
- ||| remdesivir / Generic mfg., Prevymis (letermovir) / Merck (MSD)
Clinical: Late to the game on this, but as @FranciscoMarty_ said, we're prioritizing liquid vials in all patients, except using powder vials when CrCl <30 or with concomitant cyclodextrin meds (vori, posa, letermovir). So yes, absolutely doing this #Remdesivirchat #ASPChat (Twitter) - Jun 18, 2020
- || Prevymis (letermovir) / Merck (MSD), maribavir (TAK-620) / Takeda, GSK
Clinical, Review, Journal: Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). (Pubmed Central) - Jun 12, 2020
However, management of patients with resistant or refractory cytomegalovirus infection or cytomegalovirus disease is a challenge. In this Review we summarise the reviewed literature and the recommendations of the ECIL 7 for management of cytomegalovirus in patients with haematological malignancies.
- ||| Prevymis (letermovir) / Merck (MSD)
I feel like your rating system should be cheeses instead of stars. Like this one, letermovir basically delayed CMV to after the 100-day prophylaxis, so "see you later" is apropos. 🧀🧀🧀🧀🧀🧀🧀🧀/10 (Twitter) - Jun 9, 2020
- | Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi
Trial initiation date: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab (clinicaltrials.gov) - Jun 8, 2020
P2, N=30, Not yet recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
In this Review we summarise the reviewed literature and the recommendations of the ECIL 7 for management of cytomegalovirus in patients with haematological malignancies. Initiation date: May 2020 --> Aug 2020
- | Prevymis (letermovir) / Merck (MSD)
Enrollment open: MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) (clinicaltrials.gov) - Jun 1, 2020
P3, N=20, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: May 2020 --> Aug 2020 Suspended --> Recruiting
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Treatment for Established Cytomegalovirus Infection in Transplant Recipients (Virtual) - May 29, 2020 - Abstract #ATC2020ATC_341;
More mixed outcomes were observed with higher VLs at initiation including increasing viral loads while on therapy. Letermovir overall was well tolerated.
- Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi, tacrolimus / Generic mfg.
[VIRTUAL] Use of Letermovir for Cytomegalovirus Management in Thoracic Organ Transplantation (Virtual) - May 29, 2020 - Abstract #ATC2020ATC_340;
However, caution is advised when using LTV for CMV treatment given risk for clinical failure and resistance emergence. Further study is warranted to determine the safety and efficacy of LTV for CMV treatment and prevention in SOT.
- || Prevymis (letermovir) / Merck (MSD)
Gotta throw letermovir some love just hope it can get a liiiiittle smaller soon ❤❤❤ (Twitter) - May 20, 2020
- || Prevymis (letermovir) / Merck (MSD), Trikafta (elexacaftor/tezacaftor/ivacaftor) / Vertex
Haha I only switched to that recently... letermovir has saved my ass so I think that’s my favorite. Also, trikafta. (Twitter) - May 19, 2020
- [VIRTUAL] LETERMOVIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION () - May 16, 2020 - Abstract #EHA2020EHA_2637;
Waiting for the approval of letermovir, ganciclovir plus foscarnet was initiated as a new line...In the reported case, after trying all the approved therapeutic options, letermovir was the only antiviral that achieved an effective and long-lasting response despite multiple episodes of GvHD that needed adjustment of the inmunosupressive therapy. In the setting of clinical resistance or when the drug is not used as prophylaxis, letermovir can lead to an optimal control of CMV DNAemia with a safety profile.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] FIRST YEAR REAL-LIFE EXPERIENCE ON CMV PROPHYLAXIS WITH LETERMOVIR IN HIGH-RISK PATIENTS SUBMITTED TO ALLOGENEIC STEM CELL TRANSPLANTATION () - May 16, 2020 - Abstract #EHA2020EHA_1842;
Conclusion Our real-life experience confirms that letermovir is highly effective and safe, leading to a significant drop in CMV clinically significant infections. The amelioration of other important transplant-related outcomes by day +100 (CMV disease, bacterial and fungal infections and aGVHD), although non significant, is of interest as it can potentially translates into an improvement of long term survival of allotransplanted patients.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] ORALLY ADMINISTERED LETERMOVIR PROPHYLAXIS IN ALLOGENEIC HAEMATOPOEITIC CELL TRANSPLANT RECIPIENTS: A REAL-LIFE PARADIGM () - May 16, 2020 - Abstract #EHA2020EHA_1321;
Conclusion LET prophylaxis appears to be an effective approach in high-risk allo-HCTr, with only 8% of breakthrough-cs-CMV infection. CMVqPCR remained below the LOQ in 95% of 285 tested samples.
- | Prevymis (letermovir) / Merck (MSD)
Trial suspension: MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) (clinicaltrials.gov) - May 6, 2020
P3, N=20, Suspended, Sponsor: Merck Sharp & Dohme Corp.
CMVqPCR remained below the LOQ in 95% of 285 tested samples. Recruiting --> Suspended
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Single Center Experience with Use of Letermovir for CMV Prophylaxis or Treatment in Thoracic Organ Transplant Recipients. (Pubmed Central) - May 1, 2020
Letermovir was well tolerated with only minor side effects reported; however, the rate of development of CMV DNAemia on prophylaxis was considerable. Further study of the dosing and efficacy of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients is warranted.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal, Real-World Evidence: Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real world experience. (Pubmed Central) - May 1, 2020
No recurrent reactivation was seen with secondary prophylaxis of an additional 14 patients. Our experience demonstrates the efficacy of letermovir in a real-world setting for CMV prevention for the first 14 weeks and continued efficacy when given longer than 14 weeks after allogeneic stem cell transplantation or as secondary prophylaxis.
- | brincidofovir oral (CMX-001 oral) / Chimerix, Prevymis (letermovir) / Merck (MSD), maribavir (TAK-620) / Takeda, GSK
Journal: Updates on antiviral drugs for cytomegalovirus prevention and treatment. (Pubmed Central) - Apr 15, 2020
Our experience demonstrates the efficacy of letermovir in a real-world setting for CMV prevention for the first 14 weeks and continued efficacy when given longer than 14 weeks after allogeneic stem cell transplantation or as secondary prophylaxis. Optimal treatment, influenced by recent advances in the field, including management of resistant virus, results in better outcomes with this significant and virulent virus.
- | Prevymis (letermovir) / Merck (MSD)
Review, Journal: Infectious Complications Following Kidney Transplantation-A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota. (Pubmed Central) - Apr 14, 2020
In addition, there have been the development of medications targeting the growing burden of resistant cytomegalovirus, as well as the discovery of the potentially important role of the gastrointestinal microbiota in the pathogenesis of post-transplant infection. In this narrative review, we will discuss these three advances and their potential implications for clinical practice.
- | Prevymis (letermovir) / Merck (MSD)
Journal: Advances in the treatment of cytomegalovirus. (Pubmed Central) - Apr 10, 2020
In this narrative review, we will discuss these three advances and their potential implications for clinical practice. We need to understand what immune responses are required to control HCMV, and how best to raise these immune responses with a vaccine.
- |||| Prevymis (letermovir) / Merck (MSD)
Clinical: Our postmarketing study of 25 alloSCT patients vs >100 historical controls. Bottom line is #letermovir works. Clinical “real‐world” experience with letermovir for prevention of #CMV infection in alloHCT recipients. @FranciscoMarty_ #bmtsm https://t.co/jFT0emEWoG (Twitter) - Apr 9, 2020